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Rational Revalidation 
Hosam Aleem, Tim McCarthy and Rodger Edwards 
 
 
The economic problems the world is currently facing have resulted in severe 
reductions in capital investments, hence a drive for retrofit to increase 
efficiency and make the most of existing assets. 
Although this is the case in many industries, what compounds the situation in 
the pharmaceutical industry is the slowdown in development of new drugs. 
This has led to alternative strategies such as outsourcing R&D to Universities 
and small Biotechs. Unfortunately new approaches based on “omics” and 
“Systems Biology” have not delivered any breakthroughs yet. Furthermore, on 
the factory floor, novel technologies such as Process Analytical Technology 
(PAT) and continuous processing have not become main stream yet as they 
require specialised knowledge and expertise that is not readily available 
except possibly to the large pharma companies. 
Recent regulatory fines of some manufacturers, price controls in Europe and 
the uncertainty regarding Health Care reforms in the US compound the 
situation even further. 
All the above call for integrating the economic issues with the technical ones 
in the operations of the pharma industry. A major issue in the industry is 
assessing and managing risk to the product, as for example in ICH Q9 [1]. In 
the current economic climate however, the scope of risk should be widened to 
include risk to the business as well. Without a business there won’t be a 
product for which to assess the risk! The original quality standard ISO 9001 of 
1987 is an example of a quality management system implementation that did 
not take economic factors into account. It became a bureaucratic burden that 
did not deliver its full potential, a situation which was subsequently rectified in 
the 2000 version.   
 
In this article we consider one of the costly aspects of pharmaceutical 
operation, that is validation, in particular revalidation which will become 
exceedingly important in view of the decline in capital investment in the 
current economic climate as mentioned above.  
 
We start by giving justification, i.e. why we may need to revalidate a system. 
Next we outline a strategy to prioritise among the systems to be revalidated 
and to decide on what to revalidate, how and when. We then consider how to 
identify the need for revalidation and to reduce this need. Next we discuss the 
costs associated with revalidation, and finally the different business models 
for approaching the problem. Throughout we attempt to integrate the business 
decisions with the technical ones in a pragmatic way. Having said that, we 
should make it absolutely clear at the outset that this does not in any way 
mean compromising product quality or patient safety, as those are a given in 
the pharma industry for ethical and regulatory reasons, in addition to business 
ones as well (corporate image and avoiding litigations).  
 
In our context, we will use the term system in a broad sense to incorporate the 
process, the equipment on which it is implemented and the procedure to 
Aleem, H, McCarthy T and Edwards R, Rational Revalidation,  Journal of Validation Technology V16 
No 2 pp83-92  2010 
Journal of Validation Technology  Spring 2010 2




It is not uncommon in the pharmaceutical industry to view validation as a one-
off activity to be performed once, and not to be revisited unless a major 
change to a system takes place. In fact, validation should be regarded as a 
state to maintain rather than an activity to perform. 
 
There are several reasons for revalidating a system (Figure 1), the most 
compelling of course is that it is often a regulatory requirement. Regulatory 
authorities mandate revalidation after a change to a process (including 
equipment, instruments, procedures and methods) that may impact product 
quality. The European Union (EU) GMP in addition, refers to periodic 
revalidation irrespective of such change [2]. Indeed, chapter five in the EU 
GMP entitled “Production” states that “Processes and procedures should 
undergo periodic critical re-validation to ensure that they remain capable of 
achieving the intended results”. Furthermore, Annex 15 of the same GMP 
entitled “Qualification and Validation” states that “Facilities, systems, 
equipment and processes should be periodically evaluated to verify that they 
are still operating in a valid manner”, although this requires only an evaluation 
of the validated status of a system, if this leads to unacceptable results 
revalidation may be expected.  
Periodic revalidation is also required by the World Health Organisation (WHO) 
guidelines on GMP [3]. Annex 4 of the WHO Good Manufacturing Practices 
entitled “Supplementary guidelines on good manufacturing practices: 
validation” states that “There should be periodic revalidation, as well as 
revalidation after changes”. The fact that the WHO is an international body (as 
opposed to a multinational one such as the EU or PIC/S) indicates a degree 

















Figure 1: Possible drivers for revalidation 
 
Possible Drivers for Revalidation 
 
 Changes in the process 
 Changes in regulations 
 Changes in regulatory expectations of 
current regulations  
 Changes in industry or company best 
practices 
 Maintaining an updated view of the 
process, audit readiness. 
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Other regulations introduced in the past such as the FDA 21 CFR Part 11 
addressing electronic records and electronic signatures, necessitated the 
revalidation or at least the assessment of legacy systems that were in place 
before such regulation were introduced. Given the changing nature of 
technology, it is not unreasonable to expect further changes in regulations in 
the future that may cause revalidation of existing systems. PAT is an example 
of such a technology; depending on how PAT is utilised (monitoring and data 
collection vs integrating into a control loop), this may result in redefinition of 
the process and hence necessitating revalidation. 
 
Another reason for revalidation is the change in regulatory expectations even 
when the regulations themselves do not change, which often manifests itself 
in the change in focus of regulatory inspections. This is also evident in the 
changes and updates to existing guidance documents by regulatory 
authorities or the introduction of new ones. A prominent example of that is 
again the change in regulatory expectations with regard to the implementation 
of Part 11 even though the regulation itself did not change [4]. Indeed this has 
also been the case with validation altogether over the past three decades. 
Changes in regulatory expectations can also be inferred from warning letters 
or comments from pre-inspection assessments by regulatory authorities.  
It should be noted that the recent FDA draft guidance for process validation 
[5] has removed the explicit reference to revalidation that was in the original 
1987 guidance document. Instead, it suggests a system life cycle approach 
that incorporates “continued process verification”, which in essence is 
validation maintenance. 
 
Changes that occur in the practice of validation in industry may cause a firm 
to revalidate its systems to align itself with current best practices. The 
introduction of the ISPE Baseline Guide 5: Commissioning & Qualification and 
its impact on the way qualification is performed in industry is an example of 
that [6]. Such concepts as impact assessment and enhanced design review 
have become more formalised and common place with the introduction of this 
guide. This does not necessarily mean repeating the whole validation exercise 
but possibly only producing the aforementioned documents in retrospect as 
an aid for future change control. 
 
The issues outlined above related to regulations and industry best practices, 
can be regarded as external to a firm in the sense of being beyond its control. 
In contrast there are other causes for revalidation that are considered internal 
to a firm. For example in the case of mergers and acquisitions, the standards 
and practices of validation may differ between the organisations involved and 
revalidation may be desirable to align them together, especially if an existing 
facility becomes part of a global organisation with established standards. In 
addition there are the usual causes for revalidation such as following a 
change that may impact product quality, and to maintain a validated status of 
a system.  
 
A further motivation in assessing the validated status of a system is the 
benefits accrued from such an endeavour, especially from a business 
perspective. These include taking a snapshot of the status of the different 
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systems and updating it regularly thus maintaining a current view of the 
process and keeping it under control ensuring that it is always in an audit 
ready state. This update may merely involve updating the documentation and 
does not necessarily have to entail a full-fledged testing regime.  
 
Setting a revalidation strategy 
Once the need for revalidation has been identified, a strategy has to be 
formulated for carrying out this task, in particular to decide on what to 
revalidate, how and when.  
What to revalidate? 
Clearly all systems with potential impact on product quality must be kept in a 
validated state at all times. When revalidating such systems, constraints on 
resources including time, cost and expertise make prioritisation in the order of 
revalidation inevitable. The first step is thus to prioritise among the different 
systems needing revalidation.  
The common approach is to start with systems used for parenterals, followed 
by those for other less critical products such as orals then topicals. However, 
we believe that the prioritisation should also include a business aspect, i.e. 
systems that produce products that are critical for the survival of the business 
such as blockbuster drugs. Producing a parenteral that is not financially viable 
while ignoring a less critical yet profitable product will mean that eventually 
production of the former will not be sustainable and potentially neither will be 
the business as a whole.  
 
Needless to say, all products are required to be manufactured with robustly 
validated processes, however, when resources are limited there are short 
term alternatives to revalidation (Figure 2).  One such alternative is to 
temporarily discontinue production of one product until revalidation of other 
more financially viable ones is completed. A second alternative for a multi-site 
firm is to transfer production to another site that does have the resources for 
validating the process. A third alternative is to temporarily continue production 
but with additional procedural controls such as 100% inspection, additional in-
process controls and more frequent product reviews. This is similar to the 
case of manufacturing Active Pharmaceutical Ingredients (API) for 
investigational products as outlined by the ICH GMP Guide for API Q7 [7]. In 
the unlikely event that none of the above options is attainable, production can 
be contracted out. It should be emphasised however, that those are only 
temporary measures and are not meant to replace performing the required 
revalidation exercise, unless of course moving a product to another site, 
contracting it out or possibly licensing it or even selling the intellectual 
property right (IPR) to another manufacturer is part of the firm’s strategic 
objectives. It should also be noted that these options can apply to the original 
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Figure 2: Temporary options for a process awaiting revalidation 
 
Having decided on the order in which the different systems will be revalidated, 
next comes prioritisation within a system (figure 3). This means deciding on 
which functions and features within a system to validate. Such decisions will 
likely be different from those of the original validation. It is not uncommon, 
especially in turn key projects that contractual and Health and Safety issues 
be addressed as an adjunct to the validation exercise as this is more 
convenient and cost effective for the contractor, in effect all forming part of 






Figure 3: Prioritisation for revalidation 
 
The requirements to be verified for any system can be classified into two main 
categories business requirements (for example capacities of lines), and 
regulatory requirements (Figure 3). The latter in turn are further classified into 
Temporary Alternatives for Revalidation 
 
 Discontinue production until revalidation is ready 
 Transfer production to another site within the 
organisation capable of validating the process 
 Impose additional procedural controls (such as 
100% inspection) 
 Outsource manufacturing 
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GxP requirements and others including Environmental, Health and Safety 
(EHS), and statutory. We believe that in the case of revalidation, only GxP 
requirements are to be verified. This does not mean that other regulatory and 
business requirements are not important, it only means that those while still 
need to be verified, are outside the scope of the revalidation exercise.   
How to revalidate? 
Now we turn our attention to the extent revalidation is to be performed, i.e. 
setting the acceptance criteria by which to judge the process. In a new 
project, and when ordering new equipment the full extent of its usage is not 
always known before hand. Specifications are thus set both for current and 
expected future usage. Factory acceptance testing (FAT), Site acceptance 
testing (SAT) and indeed validation, often test against such specifications that 
in many instances correspond to the performance limits of the equipment. 
One of the purposes of that is to ensure that contractual obligations on the 
supplier are met. In revalidation however, the purpose is to test an existing 
process against known requirements that may be in a much narrower range 
than that of the equipment operating range.  
 
Revalidation should be against the current process requirements, if those do 
not formally exist then a “realistic” user requirement specification (URS) 
should be drawn in retrospect as a starting point. This should be tested 
against, rather than the full range of the equipment specifications. Examples 
of such a case include a mixer that is operated at certain speeds that are less 
than its maximum possible. In such a case there is no point in qualifying this 
maximum, which is not employed in the process and may possibly be 
unachievable, especially if the equipment has been in operation for many 
years. Similarly, line speed for a packaging line for example or speed of a 
depyrogenation tunnel that is known to operate at a speed much slower than 
its maximum to guarantee performance. Another example is for autoclaves 
that normally include several types of sterilisation cycles only a subset of 
which is utilised, hence no need to try to validate the performance of all of 
them. It is of course important to emphasize in the validation report the 
parameters for which the system is validated, in case the equipment is 
needed in the future for a different process. 
 
Thus in revalidation, the purpose is to verify process requirements rather than 
other engineering requirements such as throughput or capacity, as meeting 
these does not guarantee meeting product specifications. The problem of loss 
in throughput will still need to be addressed albeit on a more strategic level 
than that of revalidation, such as site capacity expansion or major equipment 
overhaul. 
When to revalidate? 
According to all GMP regulations, any change with potential impact on 
product quality must be assessed, with revalidation as a possible outcome, 
indeed this falls in the realm of change control. Additionally, as outlined in the 
EU GMP and the WHO guidelines, this assessment should be carried out 
periodically. We look at those issues here and try to put them in a unified 
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framework. We classify the need for revalidation into time based and event 
based (Figure 4). 
 
Change control 
Event based revalidation essentially refers to revalidation following a change. 
This change can be either inadvertent or predetermined. The former means 
that the change has to be performed in order to be able to keep producing the 
concerned product with the required specifications. This can be the case for 
example when a part with impact on product quality malfunctions and has to 
be replaced. This kind of change is in essence unplanned. 
Another example is when a change in regulation causes a part to become 
unsuitable for production even if it is functioning correctly, possibly due to 
changes in material certification requirements. In such a case the replacement 
will have to be revalidated if the original part was deemed GMP critical.  In this 
sense a firm does not have the choice of not performing the revalidation, 





Figure 4: When to revalidate 
 
Predetermined changes on the other hand are planned ahead of time. Those 
can be further classified according to the purpose into reactive and proactive. 
The former are changes in reaction to a recurring problem, which, while not 
causing stoppage or non-conformity, may cause repeated product problems in 
the long run. Proactive changes are ones whose purpose is to improve the 
process without it currently suffering any problems. This improvement can be 
for example to narrow product variability in spite of being already in spec, or 
for technical improvement like replacing a machine part with a more efficient 
one. It can also be for purely economic reasons such as increasing 
throughput or reducing energy consumption. Such proactive changes can fall 
under process optimisation, be it the production process or the business 
process. Those would naturally take lower priority than unplanned changes 
whose purpose is to keep production going and maintaining product quality.  
In either case, whether the change is planned or unplanned, a rigorous 
change control procedure should be in place. For the planned changes, this 
should stipulate the assessment of the change and its impact on product 
quality and process integrity in addition to health and safety issues when 
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necessary, before the change is implemented. This will ensure not only that 
the resulting system after change is compliant, but also that other processes 
are not affected while the change is taking place. An example of this is when 
modifications are made to a hall or a building that houses other systems, or to 
utility lines that feed other processes. Such change control procedures would 
also ensure updating documentation and records post modification. Similarly 
for unplanned changes. 
 
Sterilisation and aseptic processes 
Time based revalidation, as is evident from the term, is performed periodically 
and is most common in aseptic processing and sterilisation. It is required by 
the WHO guidelines on GMP. The timing can be based on operating time or 
calendar time. The choice of which approach to take is based primarily on the 
risk to product quality, in addition to economic factors. Most commonly in 
validation a calendar-time based approach is taken because it is easier to 
plan and implement, however, this is not necessarily always the best choice 
from an economic point of view. Consider the case of a system that is rarely 
used due to low demand on its product. It may not be economically sound to 
validate it periodically in spite of the low utilisation as there is potential for it 
not being used between two consecutive validations. On the other extreme, 
there is a system that is in continual usage possibly on shift basis, for such a 
system taking a purely calendar-time based approach can be too risky. If at 
revalidation the system was found to be in significant deviation, this would 
jeopardise the entire product that has been produced since the last successful 
validation. In such a case revalidation based on the number of batches 
produced may be safer both to product quality and economically. Thus in 
practical terms and to reduce the risk to product quality, in this particular case 
the shorter of both times should be taken. 
The idea of operating time based actions is common in preventive 
maintenance programmes whereby different parts are replaced after certain 
hours in operation. In validation this corresponds to the number of batches 
produced. 
The essence of this section is that the choice of when to revalidate, whether it 
is event based (planned or unplanned change) or time based (operating or 
calendar time) is that it should ultimately be based on potential risk to the 
product. 
It is worth mentioning that the concepts of time based and event based 
actions come from the field of programmable control, where time based refers 
to timers while event based refers to counters, activation of limit switches or 
other conditions. Strictly speaking one can consider time based actions as 
event based ones whereby the elapsing of the time period is itself the event. 
However, the convention has been to treat them as distinct and we follow this 
convention. 
 
How to identify the need for revalidation and reduce it? 
Ultimately one can argue that the need for revalidation arises due to the 
occurrence of a change. This change may be known and decided, whether 
planned or unplanned.  Alternatively, it can occur without being detected, 
which time- based revalidation attempts to mitigate [3], as waiting for the 
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change to manifest itself in an out of specification product is too late from both 
quality and business points of view.  Hence to take a more structured 
approach, there should be mechanisms to detect and if possible predict this 
change as soon as possible (Figure 5).   
Such mechanisms already exist in practice although not always tied to 
validation, a powerful one of which is Statistical Process Control (SPC).  
SPC allows the continuous monitoring of the process and can detect early on, 
gradual shifts from its current (ideally controlled) state. The basis of SPC is to 
maintain the process in a state of “statistical control”, meaning that its only 
variability is due to “chance causes” and does not include any “assignable 
causes” [8]. Hence when an SPC chart detects an out of control condition, this 
signals that a change has occurred and should prompt investigation that may 
lead to revalidation. It should be noted that in the statistical sense, an out of 
control condition does not necessarily mean an out of specification product, 
however, such a condition if not addressed may lead to a non-conformity. 
Thus SPC serves as an early warning against non-conformity. There are 
variations on SPC that make it more discriminating in diagnosis and hence a 
more powerful tool, one such extension is Multivariate SPC (MSPC) [9].  
SPC is a convenient tool and can be implemented at minimal cost as many 
modern systems include the required functionality as standard. This includes 
data gathering and processing such as calculating means, standard 
deviations and control limits. Examples of such systems include modern tablet 
presses and tablet autotesters. When applying SPC however, one should be 
aware of its underlying assumptions and consequently its limitations.  
 
Another mechanism that is currently used is the Product Quality Review which 
has to be conducted periodically as mandated by the GMPs. As part of this 
exercise according to the EU GMP “A review of critical in-process controls 
and finished product results” should take place, in addition to a host of other 
reviews [2]. Such reviews would detect any major deviations in the process 
and would hence trigger an investigation that may lead to revalidation of one 
or more of the systems associated with this deviation. Such a product quality 
review already takes place on regular basis and hence will not constitute any 
additional cost. Naturally the usefulness of this exercise in detecting the need 
for revalidation early enough depends on the frequency with which it is 
conducted. As with the case of periodic revalidation, risk to the product is a 
factor in the choice of the review period. The common practice at present is 
that it is conducted annually for most products. 
 
To reduce the need for revalidation (Figure 5), a firm should ensure the timely 
execution of effective preventive maintenance plans. This will help keep 
equipment at a high level of performance, hence reducing its variability and 
reducing problems with the processes utilising it, and subsequently the need 
for revalidation. Another important factor that contributes to reducing this 
need, is strictly executing the calibration plan. It is the measuring instruments 
and devices that detect any deviations from specifications. Thus, the reliability 
of the decisions based on their results including the costly decision to 
revalidate a system, will depend on the accuracy of those measurements.  
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Figure 5: Some means for detecting the need for revalidation and reducing it 
 
Costs associated with revalidation 
We now focus on the business aspects of revalidation, these include its cost 
and the alternative business decisions associated with it. In this article we 
attempt to rationalise the revalidation process in the wide sense including 
aspects of its management process.  
The most costly phase of revalidation is when performing it for the first time. 
This is especially so for systems that have been in operation for a long time 
as there is potential risk of drifting from the original validated status. The high 
cost of the first revalidation for such systems is due to two main reasons. 
Firstly some aspects of the validation status may either be not known or 
cannot be verified, and hence there is a potentially large cost involved in the 
assessment of this status. Secondly, a system may have approached a point 
where the cumulative effect of minor changes increases the risk of it 
becoming sufficiently deviated from its initial validated state that the cost of 
bringing it back into this state will be high. We look at those two costs (Figure 
6). 
Cost of assessment of the validation status 
The major contribution to the assessment cost is the difficulty in locating the 
necessary information about a system, in particular about the equipment used 
in the process. This may be due to a piece of equipment being so old that its 
documents may have been misplaced or possibly lost altogether. Such 
important documents include validation files with all the supporting certificates 
and reports, and possibly even operation and maintenance manuals for a 
machine. Another cause for this difficulty is the case where a machine has 
been relocated from another site but not all the documents have been 
relocated with it or were lost in transit. Or they may be available but in a 
different language as is the case of a firm having plants in different countries. 
Those scenarios are not unrealistic in light of the many mergers and 
acquisitions that overtook the industry in the past decade, with the 
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subsequent close down or downsizing of plants in different locations. The time 
taken to locate documents and information is time taken off production and 
hence indirectly translates into financial cost. In addition there are the direct 
costs associated with the validation personnel involved in this assessment. 
Cost of performing the revalidation 
This is the cost of actually performing the tests, recording the results and 
reporting the conclusions, in addition to taking the equipment and systems out 
of production. However, there are other costs associated with this issue.   
Due to the potential loss of documents mentioned above, some of those will 
have to be reproduced. This can be a lengthy exercise, as depending on 
which part of the validation lifecycle has missing documents, the situation can 
involve a major revalidation exercise including generating a URS.  
Even if all the documents are available, for an old piece of equipment the 
change in regulations or regulatory expectations outlined earlier may 
necessitate obtaining additional data that was not required in the past. This is 
especially so with processes that were controlled with legacy computer 
systems and where source code availability was not a requirement, or 
equipment that has product contact parts or lubricants that were acceptable in 
the past but are not any longer. Obtaining such data can be a challenge 
because a supplier may not be in business anymore or the particular model in 
question may have been discontinued and no documents relating to it can be 
issued. Yet in another scenario, the equipment model may still be in 
production by the supplier but certain information about it is not available or is 
not normally generated by the vendor to begin with. This is not an uncommon 
case with suppliers for whom the pharmaceutical market represents a small 
share of their overall business. Again such missing information will have to be 
generated by the pharmaceutical firm and can be very costly, such as the 
case with positive material identification. 
In addition, there is of course the cost of actually performing the revalidation 
tests even if all the necessary information and documents are available; this 
includes the time, labour, instruments, and the product or placebo if required. 
Finally, as in the case of assessment costs, there is the cost of lost 
opportunity, i.e. the time that the equipment is out of use and the personnel 
are taken off their regular jobs. 
 
Based on the above costs, in conjunction with the historical data about the 
performance of a given process in addition to the possible lack of support 
from equipment suppliers, a decision can be made about what to include in 
the revalidation programme. For example, if in-process data and the regular 
Product Quality Reviews indicate a recurring problem from a given piece of 
equipment, and in addition this is coupled with missing or unobtainable data to 
verify its performance, then it might be more cost effective to replace it 
altogether. This will save the time and costs involved in assessing the state of 
this equipment and bringing it up to the current expectations with respect to 
validation standards. In a wider context, this would apply to all the systems on 
site needing validation and can help to narrow down the prioritisation process 
mentioned earlier. More importantly it will help reduce the risks associated, by 
replacing problematic systems with new ones that can be guaranteed to give 
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superior performance and compliance, hence becoming more economic in the 
longer term.  
 
The business model 
Once the scope of the revalidation exercise is decided, the business approach 
to executing it has to be determined as this will enable setting a budget, 
targets and milestones, i.e. a plan. We are still in the context of the first 
revalidation as it is the most resource demanding but also the one with the 
most benefit, as subsequent revalidations will be merely maintaining the new 
status achieved, through strictly enforcing a change control procedure.  
There are two main business options for performing the first and major 
revalidation, either to use in house staff or contract staff. We look at each 
briefly below (Figure 6). 
In house staff 
Two approaches can be taken in using in-house staff on a revalidation project. 
The first is to use the regular validation staff to perform this task beside their 
daily validation duties. Whilst the direct cost of such an approach is low 
compared to others, experience indicates that it is hard to establish focus and 
to maintain commitment. The second approach is to form an ad-hoc 
committee to handle the revalidation project until its completion. This does 
provide better focus and more commitment but still takes a long time to 
achieve the target. 
Contract staff 
Again there are two possible approaches here. The first is to employ contract 
staff on individual basis and manage them by a competent person from the in-
house staff. This person will have to have both adequate technical abilities 
and more importantly excellent managerial skills, as s/he will have to manage 
an inhomogeneous team of individuals of different professional, industrial, 
educational and possibly cultural backgrounds (such as the case in the free 
movement of labour within the EU). This will obviously be costlier than having 
the in house staff perform the job, but will entail higher commitment and a 
defined time frame. 
 
The second option is to contract out the revalidation job, whereby a validation 
consultant/contractor will handle the job altogether with only a liaison person 
from the owner side. In terms of direct costs, this option is normally the 
costliest especially if assessment of the validation status is in the remit of the 
contractor. In addition there are indirect costs involved in auditing and 
approving such contractors as part of a firm’s supplier audit procedures. On 
the other hand however, the owner will get higher commitment with respect to 
time, and can stipulate penalties in the contract if milestones or time 
obligations are not met. Furthermore, the contractor by virtue of working on 
different projects for different customers brings in significant experience to the 
firm. The down side of employing a contractor however, is the loss of 
knowledge of the process once they have left. Attempts should be made to 
capture as much of this knowledge as possible whether in writing or in person 
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by the in-house staff. Unfortunately, again experience indicates wide 
variability in the cost and commitment of validation contractors. 
 
The purpose of this section is not to give the best approach or to provide a 
one-size-fits-all solution, but rather to present the different options to choose 
from. The final decision will not only depend on the budget a firm is 
committing to this exercise, but also on the level of expertise in the firm. For 
example some biotechnology start-ups may lack the engineering or regulatory 
experience necessary to perform validation activities (for commercial 





Figure 6: Business issues related to revalidation 
 
Once the first revalidation is completed and all the product quality impacting 
systems have been brought into compliance, it is imperative to keep them in 
this state and to avoid them drifting out of it. This will necessitate regular (in 
any of the senses mentioned earlier) revalidation or re-evaluation of those 
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systems. This can be achieved by making this re-evaluation part of the regular 
staff tasks, or by employing staff dedicated solely to managing the re-
validation and the change control processes. 
In general there are several models for utilising personnel for performing the 
validation function in an organisation, depending on where validation 
responsibilities lie. For example when validation is part of process 
development, staff may be aligned with products or product classes. When 
part of engineering, they are aligned either with facilities, e.g. certain sections 
of a factory, or with lines and equipment. Alternatively, validation can be part 
of the Quality Assurance (QA) function, in which case validation personnel 
tend to work on different projects involving different products, facilities and 
equipment. Cleaning, microbiological and analytical methods validation are 
normally within the remit of the Quality Control laboratories.  
 
Conclusion  
In this article we presented a strategy for planning and executing revalidation 
of existing systems, with particular emphasis on the first revalidation. The 
main facets of this strategy are summarised in the accompanying figures. One 
key component of it is change management as it determines the need for 
revalidation and subsequently guarantees maintaining the acquired validated 
status. We believe this approach to be a pragmatic and rational one. Its main 
essence is to base the key decisions on the potential risk associated with the 
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